Management of metabolic adverse events of targeted therapies and immune checkpoint inhibitors in cancer patients: an Associazione Italiana Oncologia Medica (AIOM)/Associazione Medici Diabetologi (AMD)/Società Italiana Farmacologia (SIF) multidisciplinary consensus position paper
- Autori: Silvestris N.; Argentiero A.; Beretta G.D.; Di Bartolo P.; Montagnani M.; Danesi R.; Ferrari P.; D'Oronzo S.; Gori S.; Russo A.; Acquati S.; Gallo M.
- Anno di pubblicazione: 2020
- Tipologia: Articolo in rivista
- Parole Chiave: diabetes; dyslipidemia; hypercholesterolemia; hyperglycemia; hypertriglyceridemia; immunotherapy; metabolic effect; targeted therapy
- OA Link: http://hdl.handle.net/10447/433144
The growing insights in the next-generation immunotherapy and the state-of-the-art advancement in targeted-agents significantly improved clinical outcome of cancer patients by pointing towards a unexplored Achilles’ heel. Novel toxicity profiles have been uncovered, representing unmet medical needs. Thus, a panel of expert provide comprehensive pharmacological and clinical evidence, to provide a patient-tailored approach to metabolic adverse events associated with novel anti-cancer treatments. Prompted by the need of a multidisciplinary cooperation, a working group of Associazione Italiana Oncologia Medica (AIOM), Associazione Medici Diabetologi (AMD) and Società Italiana Farmacologia (SIF) examined the available literature data. The identification of patient risk profile and the characterization of metabolic effects of novel anti-tumour drugs is clearly a clinical challenge that can be addressed by a multidisciplinary clinical approach. Therefore, this review pinpoints the relevance of the challenging profiling of the patient suffering from dysmetabolic conditions induced by the novel therapeutics in medical oncology.